Prime Medicine (PRME) Prepaid Assets (2021 - 2026)
Prime Medicine's (PRME) quarterly Prepaid Assets came in at $421000.0 in Q1 2026, down 97.46% YoY from $16.5 million in Q1 2025, and down 85.68% on a QoQ basis from $2.9 million in Q4 2025.
Prime Medicine (PRME) Prepaid Assets (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Prepaid Assets data on file, last reported at $421000.0 in Q1 2026.
- Quarterly Prepaid Assets fell 97.46% year-over-year to $421000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $421000.0 (down 97.46% YoY) and the FY2025 annual result came in at $2.9 million, down 56.63% from the prior year.
- Prepaid Assets retreated to $421000.0 in Q1 2026, from $2.9 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $19.2 million in Q3 2023 to a low of -$11.3 million in Q1 2024.
- A 5-year average of $4.0 million and a median of $2.9 million in 2025 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2023 — Prepaid Assets soared 781.38% — and 2024, when it plunged 383.78%.
- Tracing PRME's Prepaid Assets over 5 years: stood at $2.5 million in 2022, then fell by 8.04% to $2.3 million in 2023, then jumped by 200.67% to $6.8 million in 2024, then slumped by 56.63% to $2.9 million in 2025, then slumped by 85.68% to $421000.0 in 2026.
- The last three Prepaid Assets figures came in at $421000.0 (Q1 2026), $2.9 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.36 Mn |
| Mar 31, 2026 | 421,000.00 |
| Dec 31, 2025 | 2.94 Mn |
| Sep 30, 2025 | 2.49 Mn |
| Jun 30, 2025 | 3.03 Mn |
| Mar 31, 2025 | 16.54 Mn |
| Dec 31, 2024 | 6.78 Mn |
| Sep 30, 2024 | 9.54 Mn |
| Jun 30, 2024 | -11.30 Mn |
| Mar 31, 2024 | -11.30 Mn |
| Dec 31, 2023 | 2.25 Mn |
| Sep 30, 2023 | 19.21 Mn |
| Jun 30, 2023 | 10.87 Mn |
| Mar 31, 2023 | 3.98 Mn |
| Dec 31, 2022 | 2.45 Mn |
| Sep 30, 2022 | 2.18 Mn |
| Dec 31, 2021 | 959,000.00 |